News Olympic cyclist Chris Hoy praises cancer charity campaign Sir Chris Hoy has said he is proud of participants in the Tour de 4 cycling event he set up last year to change perceptions of stage 4 cancer.
News J&J cuts $3.3bn deal to buy eye drug developer Ollin Johnson & Johnson has agreed to buy Texas biotech Ollin Biosciences for $2.2bn upfront, adding a keenly anticipated therapy for ophthalmic disorders.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.